Post-marketing Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Fibrinogen (Primary)
- Indications Afibrinogenaemia
- Focus Adverse reactions
- Sponsors Octapharma
- 03 Mar 2021 Planned End Date changed from 1 Jan 2024 to 1 Oct 2027.
- 03 Mar 2021 Planned primary completion date changed from 1 Jan 2024 to 1 Oct 2027.
- 03 Mar 2021 Status changed from not yet recruiting to recruiting.